Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 1/20 | 0.48 |
| ▸ | STAT3 | P40763 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 9/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8909177 | 1.00 | MET (0.48) | METSTAT3MAPTNPSR1ALDH1A1 | |
| SCHEMBL30970390 | 0.83 | ESR1 (0.46) | MAPTALDH1A1KDM4EGAACYP1A2 | |
| SCHEMBL27273810 | 0.83 | ESR1 (0.46) | MAPTALDH1A1KDM4EGAACYP1A2 | |
| SCHEMBL12004153 | 0.81 | MAPT (0.55) | METMAPTALDH1A1KDM4EKMT2A | |
| SCHEMBL1613587 | 0.81 | MAPT (0.55) | METMAPTALDH1A1KDM4EKMT2A | |
| SCHEMBL1613586 | 0.81 | MAPT (0.55) | METMAPTALDH1A1KDM4EKMT2A | |
| SCHEMBL9150112 | 0.81 | ALDH1A1 (0.43) | MAPTALDH1A1KDM4EGAACYP1A2 | |
| SCHEMBL9150118 | 0.81 | ALDH1A1 (0.43) | MAPTALDH1A1KDM4EGAACYP1A2 | |
| SCHEMBL14078326 | 0.81 | ALDH1A1 (0.47) | METMAPTNPSR1ALDH1A1KDM4E | |
| SCHEMBL18163764 | 0.80 | CNKSR1 (0.57) | STAT3MAPTNPSR1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2661431-B1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2018-07-11 | — | — | EP | disclosed |
| US-9073902-B2 | Substituted quinoxaline carboxylic acid compounds for the inhibition of PASK | BIOENERGENIX, LLC (US) | 2015-07-07 | — | — | US | disclosed |
| US-9073902-B2 | Substituted quinoxaline carboxylic acid compounds for the inhibition of PASK | BIOENERGENIX, LLC (US) | 2015-07-07 | — | — | US | disclosed |
| US-20120220589-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-08-30 | — | — | US | disclosed |
| WO-2012094462-A2 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-07-12 | — | — | WO | disclosed |
| US-5670664-A | Photosensitive organic compounds that release carbon monoxide upon illumination | UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE (US) | 1997-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220589-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | PASK, PDXK, PANK2 | MET 3190/4885STAT3 2285/4885MAPT 3629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.